Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

European Notebook: Sanofi Exiting Toulouse; Job Cuts At Pierre Fabre; Generics Suspended In Four States

Executive Summary

The newly formed European Commission sets out plans to improve industrial growth and international trade while leading French pharma companies Sanofi and Pierre Fabre announce plans to trim their R&D workforces. Asian companies in contrast are seeking growth opportunities in Europe, including India’s Cipla and Thailand’s CP Group.

You may also be interested in...



U.K. Life Sciences Minister Faces Hurdles To Plans To Speed Drug Access

British life sciences minister George Freeman has launched ambitious plans to speed access to drugs by cutting drug development times by a third – but his plans face many hurdles.

Sanofi Pulls Back On French Layoff Plans After Government Pressure

Sanofi says it will cut up to 900 jobs in France over the next three years to make its R&D operations there more efficient – that’s less than half the number foreshadowed in July by French trade unions and after the drug maker came under public pressure from the country’s left-wing government.

Pipeline Watch: Phase III Readouts in Wilson Disease, Parkinson's Disease And COVID-19

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Topics

Related Companies

UsernamePublicRestriction

Register

PS056547

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel